Most Expensive Prescription Drugs

Ranked by average cost per 30-day supply claim under Medicare Part D.

#	Drug	Condition	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Spinraza Nusinersen	Rare Diseases	$73,000.00	$876.0M	-14.2%	Yes
2	Soliris Eculizumab	Blood Disorders	$68,556.00	$1.2B	-8.4%	Yes
3	Ultomiris Ravulizumab	Blood Disorders	$65,292.00	$1.6B	+32.4%	Yes
4	Hemlibra Emicizumab	Blood Disorders	$34,278.00	$1.2B	+18.6%	Yes
5	Evrysdi Risdiplam	Rare Diseases	$31,500.00	$567.0M	+42.6%	Yes
6	Eloctate Antihemophilic Factor (FC fusion)	Blood Disorders	$31,500.00	$567.0M	-4.6%	Yes
7	Alprolix Coagulation Factor IX (FC fusion)	Blood Disorders	$28,750.00	$345.0M	-8.4%	Yes
8	Mavyret Glecaprevir/Pibrentasvir	Hepatitis C	$26,250.00	$945.0M	-21.4%	Yes
9	Epclusa Sofosbuvir/Velpatasvir	Hepatitis C	$26,143.00	$1.1B	-15.7%	Yes
10	Advate Antihemophilic Factor (rDNA)	Blood Disorders	$25,333.00	$456.0M	-14.6%	Yes
11	Harvoni Ledipasvir/Sofosbuvir	Hepatitis C	$24,958.00	$1.2B	-38.2%	No
12	Adynovate Antihemophilic Factor (PEG)	Blood Disorders	$24,643.00	$345.0M	-6.2%	Yes
13	Ocrevus Ocrelizumab	Multiple Sclerosis	$23,635.00	$3.5B	+16.5%	Yes
14	Trogarzo Ibalizumab	HIV	$22,250.00	$89.0M	+8.4%	Yes
15	Remodulin Treprostinil (SC/IV)	Pulmonary Hypertension	$20,857.00	$876.0M	+8.6%	Yes
16	Pemazyre Pemigatinib	Cancer	$20,500.00	$123.0M	+14.2%	Yes
17	Xospata Gilteritinib	Cancer	$19,500.00	$234.0M	+8.6%	Yes
18	Empaveli Pegcetacoplan (PNH)	Blood Disorders	$19,500.00	$234.0M	+28.4%	Yes
19	Tibsovo Ivosidenib	Cancer	$19,167.00	$345.0M	+24.5%	Yes
20	Flolan Epoprostenol	Pulmonary Hypertension	$19,167.00	$345.0M	-4.8%	Yes
21	Keytruda Pembrolizumab	Cancer	$18,176.00	$7.2B	+28.6%	No
22	Orenitram Treprostinil (oral)	Pulmonary Hypertension	$17,719.00	$567.0M	+12.4%	Yes
23	Pomalyst Pomalidomide	Cancer	$17,250.00	$3.3B	+4.7%	No
24	Enhertu Fam-Trastuzumab Deruxtecan	Cancer	$16,930.00	$1.5B	+125.4%	Yes
25	Inrebic Fedratinib	Cancer	$16,714.00	$234.0M	+12.3%	Yes
26	Opdivo Nivolumab	Cancer	$15,821.00	$5.1B	+15.8%	Yes
27	Adcetris Brentuximab Vedotin	Cancer	$15,750.00	$567.0M	+6.8%	Yes
28	Kalydeco Ivacaftor	Cystic Fibrosis	$15,750.00	$567.0M	-8.4%	Yes
29	Trodelvy Sacituzumab Govitecan	Cancer	$15,643.00	$876.0M	+68.4%	Yes
30	Tabrecta Capmatinib	Cancer	$15,375.00	$123.0M	+32.4%	Yes
31	Tepmetko Tepotinib	Cancer	$15,375.00	$123.0M	+24.6%	Yes
32	Vosevi Sofosbuvir/Velpatasvir/Voxilaprevir	Hepatitis C	$14,833.00	$178.0M	-28.6%	Yes
33	Rozlytrek Entrectinib	Cancer	$14,833.00	$178.0M	+18.6%	Yes
34	Gavreto Pralsetinib	Cancer	$14,833.00	$178.0M	+28.4%	Yes
35	Lemtrada Alemtuzumab	Multiple Sclerosis	$14,833.00	$178.0M	-14.2%	Yes
36	Idhifa Enasidenib	Cancer	$14,833.00	$89.0M	-12.4%	Yes
37	Kadcyla Ado-Trastuzumab Emtansine	Cancer	$14,515.00	$987.0M	-8.2%	Yes
38	Padcev Enfortumab Vedotin	Cancer	$14,515.00	$987.0M	+82.3%	Yes
39	Retevmo Selpercatinib	Cancer	$14,375.00	$345.0M	+56.3%	Yes
40	Tukysa Tucatinib	Cancer	$14,375.00	$345.0M	+32.1%	Yes
41	Tyvaso Treprostinil (inhaled)	Pulmonary Hypertension	$14,349.00	$1.2B	+24.6%	Yes
42	Sarclisa Isatuximab	Cancer	$14,250.00	$456.0M	+28.9%	Yes
43	Lorbrena Lorlatinib	Cancer	$14,250.00	$456.0M	+42.5%	Yes
44	Libtayo Cemiplimab	Cancer	$14,125.00	$678.0M	+35.6%	Yes
45	Trikafta Elexacaftor/Tezacaftor/Ivacaftor	Cystic Fibrosis	$13,935.00	$3.5B	+18.4%	Yes
46	Opdualag Nivolumab/Relatlimab	Cancer	$13,500.00	$567.0M	+86.4%	Yes
47	Yervoy Ipilimumab	Cancer	$13,058.00	$1.1B	+8.9%	Yes
48	Lumakras Sotorasib	Cancer	$13,000.00	$234.0M	+28.4%	Yes
49	Thalomid Thalidomide	Cancer	$13,000.00	$234.0M	-18.6%	Yes
50	Sovaldi Sofosbuvir	Hepatitis C	$13,000.00	$234.0M	-42.4%	Yes